BDSXBiodesix, Inc.
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of …
Industry Peers
Diagnostics & Research| Headline | Source | Time |
|---|---|---|
Older | ||
 Biodesix (BDSX) Q2 2026 Earnings Call Transcript Revenue jumped 34% as diagnostic testing surged on primary care adoption gains. | ||
 Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference Biodesix (NASDAQ:BDSX) said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy. Speaking at the Canaccord Genuity Growth Conference, Chief E | ||
 Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue? Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. | ||
 Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | ||
 Biodesix, Inc. Q2 2026 Earnings Call Summary Moby summary of Biodesix, Inc.'s Q2 2026 earnings call | ||
Biodesix Inc (BDSX) (Q2 2026) Earnings Call Highlights: Revenue Surges 34% on Strong Diagnostic ... Biodesix Inc (BDSX) posts robust Q2 2026 results with 42% growth in diagnostic testing revenue and improved margins, while maintaining full-year guidance. | ||
 Biodesix Q2 Earnings Call Highlights Biodesix (NASDAQ:BDSX) reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its commercial organization. Total revenue was $26.9 million for the quarter, while diagnostic testing | ||
 Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates Biodesix (BDSX) delivered earnings and revenue surprises of +17.44% and +2.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in. | ||